Capillary western alternative for drug discovery

Screen more compounds and doses,
without the capital request

Up to 96 conditions per run on the equipment your group already owns, in a workflow your team and your CRO have already validated. No six-figure instrument, no proprietary cartridges.

No capital request

A tank, not a six-figure instrument.

96 conditions per run

Compounds, doses, and timepoints on one gel.

Peer-reviewed, NIH-funded

Data your QA team can review first.

Nothing new to qualify

Same antibodies and protocols as today.

Your western blot screening panel outgrew the gel, and the fix is stuck in procurement

Compounds, doses, and timepoints produce more conditions than a standard gel can hold. Automated capillary platforms solve the throughput problem, but they take a capital request, a procurement cycle, proprietary consumables, and a new instrument for QA to qualify.

Adding traditional gel capacity works until the panel grows again. Running 96 conditions that way takes roughly seven gels and six to seven separate transfer and antibody rounds, and the gap widens with every expansion.

G48 and G96 hold 48 or 96 samples on a single gel and run on equipment your group already owns, in the same workflow your team and your CRO already validated.

Scaling a 96-condition panel

1 gelVersus roughly seven traditional gels
No capexHT-1 tank only, no capital approval cycle
StandardReagents throughout, with no cartridge lock-in
ZeroNew instruments for QA or a CRO to qualify

How high throughput western blot screening runs on one gel

A standard western blot from start to finish. The gel holds more samples; nothing else about the process changes.

Step 1: Load

Target engagement and biomarker panels on one gel

Up to 96 conditions load at up to 30 microliters per well, using existing sample prep and Laemmli buffer.

Step 2: Run and transfer

One run, one transfer

Run in the HT-1 horizontal tank on a standard power supply, then wet transfer to nitrocellulose or PVDF.

Step 3: Detect

Validated antibodies, existing imager

Probe with the antibodies already qualified in house or at the CRO and image on the system you have.

Scale western blot screening without capital equipment

  • Up to 96 conditions per run on equipment the group already owns.
  • No capital equipment request and no procurement approval cycle to wait on.
  • No proprietary consumables and no cartridge lock-in. Standard reagents throughout.
  • Nothing new for internal QA or a CRO to qualify, since the antibodies and protocols are already validated.
  • Panel size scales without headcount or capex.
  • Replicates and controls on one membrane, which keeps comparisons within a panel clean.
Dose Response

Capillary western vs. one-gel western blot

G48 / G96Automated capillary platformStandard 15-well gel
Samples per runUp to 96Up to 96, overnight15
Capital equipmentNo, HT-1 tank onlyYes, six-figure instrumentNo
ConsumablesStandard reagentsProprietary cartridgesStandard reagents
Procurement approvalNoYes, capital requestNo
New method for QA to qualifyNoYesNo
SchedulingYour bench, your timelineShared, often over-subscribed instrument timeYour bench, more gels

Western blot assay validation evidence your QA team can review first

Performance is backed by NIH-funded, peer-reviewed work that internal QA or a CRO can review before a first order, rather than a vendor benchmark.

Serial dilutions of recombinant alpha tubulin were run on a traditional western blot gel and a G96 gel, transferred to the same membrane type, incubated with the same antibodies, and detected with the same chemiluminescent substrate, showing equivalent sensitivity.

Founder-led by an active NIH-funded lab

The company was built by the scientists who hit this wall in their own research and engineered the fix.

Low-risk to validate

A loaner evaluation confirms performance on your own panel before you commit to volume.

G48 and G96 precast polyacrylamide gel specifications

  • G48: 48-well precast gel, single or multi-channel loadable.
  • G96: 96-well precast gel, runs up to 96 samples in about one hour.
  • Tris-HCl chemistry, compatible with standard buffers.
  • Up to 30 microliters loading volume per well.
  • Compatible with standard power supplies, sample types, and wet transfer systems.
  • Nitrocellulose and PVDF membranes both supported.
  • Works with standard blocking and washing buffers, antibodies, and detection chemistries.

Drug discovery western blot questions

How does this compare with buying time on our capillary platform?

The difference this page can state today is structural: no instrument purchase, no proprietary cartridges, no new platform for QA to qualify, and no waiting on shared instrument time.

Can our CRO or internal QA validate this method?

Yes. It runs on the same antibodies and protocols already validated in house or at the CRO, and there is no new instrument to qualify.

Why not just add more traditional gel capacity?

That works until the panel grows. Running 96 conditions the traditional way takes roughly seven gels and six to seven separate transfer and antibody rounds, compared with one gel and one round on G96. The gap widens as panels scale.

Is Blotting Innovations stable enough to support an ongoing program?

The company is founder-led by an active NIH-funded lab, with peer-reviewed validation behind the format. A loaner evaluation is also a low-risk way to confirm performance before committing to volume.

Bring your panel. Leave with a one-gel plan.

Share the compounds, doses, and timepoints you're running now, and we'll show you how they fit on a single G96, with no capital request and nothing new for QA to qualify.